Serum alpha fetoprotein kinetics in hepatocellular carcinoma. A case for cessation of therapy
Related Experiment Video
Updated: Aug 7, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Abstract:
As chemotherapy with adriamycin is accompanied by toxic side effects, early recognition of ineffective treatment is important. Marker kinetics, apparent half-life (AFL) and doubling time (DT), showed that in five patients with advanced hepatocellular carcinoma, adriamycin was ineffective. Failure of the chemotherapeutic regimen was apparent by the third course of treatment.
Related Concept Videos
Hepatic Drug Excretion: Influencing Factors
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

